Faysal A. Yafi

Faysal A. Yafi

Auto-generated profile, based on publicly available information

Faysal A. Yafi

University of California, Irvine Department of Urology, Irvine, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
JLJustin La
Justin La
NRNatalie H. Roberts
Natalie H. Roberts
FYFaysal A. Yafi
Faysal A. Yafi
Male sexual dysfunctions are more prevalent with aging. With increasing evidence about the impact of various diets on chronic diseases, there is a growing interest in establishing an association between various diets and men's health and sexual dysfunction. To review the current literature examining diet and dietary patterns and male sexual health. A thorough literature search of peer-reviewed publications on the association between diet and dietary patterns and male sexual health (erectile dysfunction, hypogonadism, and infertility) was carried using the online PubMed database from 1977 through 2017 with the keywords diet, dietary patterns, erectile dysfunction, male hypogonadism, low testosterone, and male infertility. Summary of significant findings on erectile function, androgen levels, and semen analysis parameters in relation to diets or dietary patterns. Thirteen studies on diet and erectile dysfunction and 15 studies on diet and testosterone levels were reviewed, including observational studies and randomized controlled trials. Thirteen studies analyzing the relation between diet and semen analysis parameters were reviewed but consisted of only cross-sectional and case-control studies. Evidence exists demonstrating the association between various diets and men's sexual health. Erectile dysfunction appears to lessen in men adhering to the Mediterranean diet. Obese and overweight men who lose weight through low-fat, low-calorie diets seem to have improvements in their erectile function and testosterone levels. Furthermore, a Western diet is associated with lower semen quality. Future prospective and randomized controlled trials are necessary to establish the benefit of diet and dietary patterns on men's sexual health. La J, Roberts NH, Yafi FA. Diet and Men's Sexual Health. Sex Med Rev 2018;6:54-68.

1 April 2018 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
FYFaysal A. Yafi
Faysal A. Yafi
ISIra D. Sharlip
Ira D. Sharlip
EBEdgardo F. Becher
Edgardo F. Becher
Phosphodiesterase type 5 inhibitors (PDE5Is) have demonstrated efficacy in the treatment of erectile dysfunction (ED). Although historically found to have limited drug-related adverse events, emerging data have suggested that PDE5Is might be associated with melanoma or recurrence of prostate cancer after radical prostatectomy. To summarize the literature on the safety of PDE5Is. A literature review was performed through PubMed from 1990 through 2016 regarding ED. Keywords used for the search were erectile dysfunction, phosphodiesterase type 5 inhibitors, sildenafil, vardenafil, tadalafil, avanafil, safety, side effects, and adverse events, among others. Visual, auditory, cardiovascular, renal, hepatic, priapic, and oncologic outcomes associated with the intake of PDE5Is for the treatment of ED, in addition to drug interactions, abuse, overdose, and the phenomenon of counterfeit medications. PDE5Is are safe drugs for the management of ED. Although recent studies have shown an increased risk of non-arteritic ischemic optic neuropathy with PDE5Is, the magnitude of that risk is small. The possibility that PDE5Is cause sensorineural hearing loss remains uncertain. PDE5Is display a safe cardiovascular profile if used according to the Princeton III Consensus guidelines. There appears to be an association between PDE5I use and melanoma but the absence of a mechanism of causation raises doubt that the association is cause and effect. PDE5Is do not increase the risk of biochemical recurrence after prostate cancer management. PDE5I abuse and use of counterfeit medications present serious global health concerns. Current data strongly support the efficacy, tolerability, and overall safety of PDE5Is for the treatment of ED. PDE5Is probably cause a small increase in the risk of non-arteritic ischemic optic neuropathy. Evidence on increased rates of melanoma and prostate cancer recurrence is weak and controversial. PDE5Is should still be considered first-line therapy for the treatment of most etiologies of ED. Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev 2018;6:242-252.

1 September 2017 in Urology
Verified
Journal Article
Closed access
SWSteven K. Wilson
Steven K. Wilson
CMCesar Mora-Estaves
Cesar Mora-Estaves
PEPaulo Egydio
Paulo Egydio
DRDavid Ralph
David Ralph
MHMohamad Habous
Mohamad Habous
FYFaysal A. Yafi
Faysal A. Yafi

1 July 2019 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
MHMarah C. Hehemann
Marah C. Hehemann
MTMaxwell Towe
Maxwell Towe
LHLinda My Huynh
Linda My Huynh
FEFarouk M. El-Khatib
Farouk M. El-Khatib
FYFaysal A. Yafi
Faysal A. Yafi
Most men seeking penile girth augmentation have physiologically normal penises but may suffer from severe preoccupation with penis size known as penile dysmorphophobic disorder. To describe the medical, procedural, and reconstructive techniques available for penile girth enhancement and to review the success and complications of each modality. A comprehensive review of peer-reviewed publications on the topic was performed through a PubMed search. Key search terms included penis, enhancement, enlargement, phalloplasty, reconstruction, girth, and augmentation. We wanted to summarize the motivations behind penile girth enhancement and review the outcomes for girth augmentation treatments. Various medical, traction, injection, prosthetic, and reconstructive modalities have been studied for penile girth enhancement, with increases in girth ranging from 0-4.9 cm. Complications were reported in a minority of patients, but they may be devastating and include penile fibrosis, sexual dysfunction, device infection, and death. A variety of penile girth augmentation techniques have been studied. Clinical guidelines are lacking, and complications of penile girth enhancement are likely underreported. Until more rigorous investigation with accurate reporting of complications is achieved, penile girth augmentation procedures should be considered experimental. Hehemann MC, Towe M, Huynh LM, et al. Penile Girth Enlargement Strategies: What's the Evidence? Sex Med 2019;7:535-547.

1 July 2019 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
MTMaxwell Towe
Maxwell Towe
LHLinda My Huynh
Linda My Huynh
FEFarouk El-Khatib
Farouk El-Khatib
JGJoshua Gonzalez
Joshua Gonzalez
LJLawrence C. Jenkins
Lawrence C. Jenkins
FYFaysal A. Yafi
Faysal A. Yafi
Sexual function after colorectal surgery is a largely ignored topic. In patients being treated for colon and rectal cancers, the risk of sexual dysfunction after surgery is high and is influenced by multiple factors. To examine the factors involved with sexual dysfunction after colorectal surgery and review gender-specific sexual complaints most reported on in the literature. A comprehensive review of peer-reviewed publications on the topic was performed through a PubMed search. Key search terms and phrases included colorectal surgery, sexual dysfunction, risk factors, cancer, erectile dysfunction, dyspareunia, and counseling. The main outcome measures were gender-specific sexual complaints after colorectal surgery and risk factors involved. The type of excision and surgical technique strongly influences sexual dysfunction risk, where newer nerve-preserving techniques seem to be associated with better sexual outcomes in contrast to more extensive surgeries. Adjunctive radiotherapy negatively affects sexual health when combined with surgical resection. The most common postoperative sexual complaints reported by men include erectile dysfunction, ejaculatory dysfunction, and dysorgasmia, whereas for women dyspareunia and poor lubrication are common. Sexual morbidity after treatment for colorectal cancer is common and inadequately addressed by healthcare providers in the preoperative setting. Towe M, Huynh LM, El-Khatib F, et al. A Review of Male and Female Sexual Function Following Colorectal Surgery. Sex Med Rev 2019;7:422-429.

6 March 2018 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
FYFaysal A. Yafi
Faysal A. Yafi
RARobert Andrianne
Robert Andrianne
LALaith Alzweri
Laith Alzweri
JBJeffrey Brady
Jeffrey Brady
MBMichael Butcher
Michael Butcher
SWSteven K. Wilson
Steven K. Wilson
Background: After radical prostatectomy (RP), erectile dysfunction, often necessitating the need for inflatable penile prosthesis (IPP) insertion, and urinary incontinence and climacturia can ensue. Aim: To assess the efficacy and safety of the mini-jupette, a mesh used to approximate the medial aspects of the 2 corporotomies at the time of IPP insertion, for the management of climacturia and urine leakage in patients with minimal incontinence. Methods: We conducted a pilot multicenter study of patients with post-RP erectile dysfunction and climacturia and/or mild urinary incontinence (≤2 pads/day [ppd]) undergoing IPP insertion with concomitant placement of a mini-jupette graft. Outcomes: Pre- and postoperative erectile function, continence and climacturia, and overall surgical outcomes were assessed. Results: 38 patients underwent the mini-jupette procedure. The mean age of the population was 65.3 years (SD = 7.7). 30 had post-RP climacturia and 32 patients had post-RP incontinence (mean = 1.3 ppd, SD = 0.8). 31 patients received Coloplast Titan, 4 received AMS 700 LGX, and 3 received AMS 700 CX IPPs. Mean corporotomy size was 2.9 cm (SD = 1.0). Mean graft measurements were 3.2 cm (SD = 0.9) for width, 3.3 cm (SD = 1.3) for length, and 11.0 cm2 (SD = 5.1) for surface area. At a mean follow-up of 5.1 months (SD = 6.9), there were 5 postoperative complications (13.2%) of which 4 required explantation. Climacturia and incontinence were subjectively improved in 92.8% and 85.7%, respectively. Mean ppd decreased by 1.3 postoperatively. Clinical Implications: The Andrianne mini-jupette is a feasible adjunct to IPP placement that can be used for subsets of patients with post-RP climacturia and/or minimal incontinence. Strengths and Limitations: Strengths of this study include the novel nature of this intervention, the multi-institutional nature of the study, and the promising results demonstrated. Limitations include the retrospective nature of the study and the heterogeneity of the techniques and grafts used by different surgeons involved. Conclusion: Longer follow-up and larger patient cohorts are needed to confirm the long-term safety and benefits of this intervention.